One of the first final-tier Road to the Kentucky Derby qualifiers worth 100-50-25-15-10 points is Saturday's $1 million Louisiana Derby (G2).

BOSTON - Praxis Precision Medicines, Inc. (NASDAQ:PRAX) announced Tuesday it will immediately convert its EMBRAVE3 registrational study for elsunersen in SCN2A developmental and epileptic ...

Praxis Precision Medicines is converting its EMBRAVE3 study of elsunersen for children suffering from a developmental disease into a single-arm study after meeting with the Food and Drug ...

Praxis Precision Medicines, Inc. (PRAX) stock is soaring in trading today, up 35% at time of writing, with shares reaching a value of $260, their highest value since the beginning of 2022. Current ...

BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Praxis Precision (PRAX) announced results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of patients with SCN2A and SCN8A developmental and epileptic ...

Praxis confirms an upcoming meeting with the FDA to discuss the results and NDA path BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage ...

Praxis Precision Medicines, Inc. - GlobeNewswire - Mon Aug 25, 3:01PM CDT BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical ...

As schools reopen this week, students are returning to classrooms where AI-powered tools are becoming more commonplace. According to a study from the Walton Family Foundation and Gallup, six in 10 ...

BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) ...